Click Chemistry Enables Modular ADC Assembly to Target Heterogeneous Tumors

Cancer cells are shape-shifters. A tumor that responds beautifully to one drug can evolve, within months, into something unrecognizable—a mosaic of cells with different vulnerabilities, different surface markers, different ways of hiding from treatment. Antibody-drug conjugates, or ADCs, have been a genuine breakthrough in oncology, delivering toxic payloads directly to tumor cells by latching onto specific molecular targets. But they work best when the target is everywhere, uniform, unavoidable. When a tumor becomes heterogeneous—when some cells are drowning in a particular receptor while others have almost none—the whole strategy begins to fray.

Researchers at Washington University School of Medicine have developed a way around this problem, and it hinges on a deceptively simple idea: what if you didn't have to engineer a new drug at all? What if you could take antibodies and ADCs that already exist, that the FDA has already approved, and make them find each other inside the body?

The team used a chemical technique called click chemistry—a form of molecular assembly that happens through bioorthogonal reactions, meaning the components bond together in living tissue without interfering with normal biology. They modified FDA-approved antibodies and HER2-directed ADCs with complementary chemical tags. When administered sequentially, these molecules circulate through the bloodstream until they encounter each other and snap together, forming complexes capable of engaging multiple tumor targets at once. The work, published in Nature, demonstrates that this modular approach produces substantially stronger antitumor activity than conventional single-target ADC therapy.

In mouse models of pancreatic, gastric, and breast cancer, the results were striking. When researchers paired HER2-directed ADCs with antibodies targeting either HER2 or EGFR—a receptor often associated with treatment resistance—the assembled complexes outperformed standard therapy. In the pancreatic cancer model, approximately 90 percent of treated mice survived for 120 days, compared to less than 80 days for animals receiving conventional ADC therapy. The advantage was particularly pronounced in tumors with low, ultralow, or heterogeneous HER2 expression, cancers that typically respond poorly to existing HER2-targeted treatments.

What makes this approach genuinely novel is its modularity. Rather than committing years and enormous resources to engineering a new bispecific antibody for each tumor profile, researchers can now rapidly pair different approved antibodies and ADCs based on what a particular patient's tumor actually looks like. The linking molecules can be synthesized in one to three days. A pathologist examines a biopsy, identifies which receptors are present and at what levels, and the therapeutic combination is assembled to order.

The researchers also engineered the platform to minimize off-target drug accumulation in the liver, a critical concern for reducing systemic toxicity. The therapeutic benefit, they note, likely stems from a combination of the chemistry itself and the underlying tumor biology—the way multiple receptors work together to pull the drug into cells, rather than relying on a single point of entry.

Although the current work focuses on HER2-targeted therapies, the team sees the approach extending far beyond. Brain cancers, notoriously difficult to treat and often heterogeneous in their receptor expression, are a particular focus. The platform could theoretically be adapted to any receptor combination, any cancer type. The authors also envision applications beyond direct cytotoxic delivery: immune modulation, diagnostic imaging, even combinatorial payload strategies where multiple drugs are delivered simultaneously. What they have created is not a single new drug but a flexible foundation—a way of thinking about how approved therapies might be recombined and customized for the specific tumor sitting in front of you.